Inflammatory mediators and cytokine networks

Inflammatory mediators and cytokine networks represent a complex system of signaling molecules, including cytokines, chemokines, and lipid mediators, that coordinate the body's response to injury and infection [StatPearls]. These networks facilitate communication between immune cells and other tissues to initiate, amplify, and eventually resolve inflammatory processes [Nature Reviews Immunology]. Dysregulation of these networks is a hallmark of numerous pathological conditions, such as rheumatoid arthritis, inflammatory bowel disease, and cytokine storm syndromes [NIH]. Therapeutic intervention typically involves targeting specific nodes within the network, such as tumor necrosis factor-alpha (TNF-alpha) or interleukin-6 (IL-6), to restore homeostatic balance [PubMed]. While highly effective in treating chronic inflammatory diseases, modulating these networks carries risks of systemic immunosuppression and opportunistic infections [FDA]. Understanding the interplay within these networks is crucial for developing precision medicines that can selectively modulate inflammation without compromising host defense [Frontiers in Immunology].

Other names

Cytokine signaling networkInflammatory cascadePro-inflammatory mediator systemCytokine-chemokine network

Drugs targeting this network typically act by neutralizing specific pro-inflammatory cytokines (e.g., monoclonal antibodies against TNF-alpha or IL-6), blocking their cognate receptors, or inhibiting downstream intracellular signaling pathways such as the JAK-STAT pathway [PubMed, Frontiers in Immunology].